- Trials with a EudraCT protocol (112)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
112 result(s) found for: Microbiology.
Displaying page 3 of 6.
EudraCT Number: 2020-001576-15 | Sponsor Protocol Number: MK-3009-029 | Start Date*: 2020-05-28 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II Open-Label, Single-arm Clinical Trial to Study the Safety, Efficacy and Pharmacokinetics of MK-3009 (Daptomycin) in Japanese Pediatric Participants Aged 1 to 17 Years with Complicated Sk... | |||||||||||||
Medical condition: Complicated Skin and Soft Tissue Infections or Bacteremia caused by Gram-positive cocci | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-002644-42 | Sponsor Protocol Number: DPM-B-305 | Start Date*: 2008-07-15 | |||||||||||
Sponsor Name:Pharmaxis Pharmaceuticals Limited | |||||||||||||
Full Title: A phase III multicenter, randomized, parallel, controlled, double blind study to investigate the safety and efficacy of inhaled mannitol over 12 months in the treatment of bronchiectasis | |||||||||||||
Medical condition: Bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001026-62 | Sponsor Protocol Number: ETGOL | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:University Hospital Dr Josep Trueta | |||||||||||||
Full Title: Benefits of inhalation of 7% hypertonic saline solution prior to ELTGOL physiotherapy, in patients with bronchiectasis. A randomized controlled trial. | |||||||||||||
Medical condition: bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001109-15 | Sponsor Protocol Number: BIOTOB | Start Date*: 2015-12-15 | |||||||||||
Sponsor Name:INSTITUTO DE INVESTIGACION SANITARIA LA FE | |||||||||||||
Full Title: A Phase III clinical trial randomized and blinded on the use of inhaled tobramycin compared with placebo in patients undergoing mechanical ventilation and colonized by Gram negative bacteria for ef... | |||||||||||||
Medical condition: critically ill patients undergoing mechanical ventilation | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002366-39 | Sponsor Protocol Number: 000000 | Start Date*: 2018-08-23 | |||||||||||
Sponsor Name:University of Oxford / Clinical Trials and Research Governance | |||||||||||||
Full Title: A pilot trial of intravenous iron for the treatment of iron deficiency in adult patients with cystic fibrosis | |||||||||||||
Medical condition: Cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004880-29 | Sponsor Protocol Number: HUB-INF-RADICAP | Start Date*: 2019-10-02 | |||||||||||
Sponsor Name:Dr. Jordi Carratalà Fernández (Servicio de Enfermedades Infecciosas) del Hospital Universitario de Bellvitge | |||||||||||||
Full Title: Phase IV randomized, controlled, open and multicentre clinical trial with two parallel groups, to assess the impact of integral molecular tests in the antimicrobial use in community-acquired pneumo... | |||||||||||||
Medical condition: Community-acquired pneumonia (CAP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-003261-18 | Sponsor Protocol Number: VITAL | Start Date*: 2019-11-22 |
Sponsor Name: | ||
Full Title: The effects of allergen immunotherapy on anti-viral immunity in patients with allergic asthma | ||
Medical condition: Allergic asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-005127-33 | Sponsor Protocol Number: UGENT_LIMOP | Start Date*: 2013-01-11 | |||||||||||
Sponsor Name:University Ghent | |||||||||||||
Full Title: Pharmacokinetic and pharmacodynamic evaluation of linezolid administered intravenously in MRSA-positive, morbidly obese patients with pneumonia. | |||||||||||||
Medical condition: MRSA-positive, morbidly obese patients with pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000609-10 | Sponsor Protocol Number: 2020-01-GMF-1 | Start Date*: 2021-07-06 | |||||||||||
Sponsor Name:Center for Surgical Science | |||||||||||||
Full Title: A combined treatment with GM-CSF, fosfomycin and metronidazole for pouchitis in ulcerative colitis patients after restorative ileal pouch anal anastomosis surgery A clinical safety and proof-of-con... | |||||||||||||
Medical condition: A combination of GM-CSF and metronidazole/fosfomycin treatment for pouchitis in Ulcerative Colitis patients after ileal-pouch-anal anastomosis surgery given as an enema or spray in the pouch. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-004402-10 | Sponsor Protocol Number: APHP180587 | Start Date*: 2020-03-11 | |||||||||||
Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP) | |||||||||||||
Full Title: Fecal transplantation to Eradicate Colonizing Emergent Superbugs | |||||||||||||
Medical condition: Patients colonized with MDR-GNB (multi-drug resistant Gram Negative bacteria ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002720-91 | Sponsor Protocol Number: HBnr02 | Start Date*: 2017-09-21 |
Sponsor Name:CyTuVax BV | ||
Full Title: Immunogenicity and safety of HBAI20 Hepatitis B vaccine in non-responders. | ||
Medical condition: In a minority of the population (5-10%) standard vaccines against Hepatitis-B do not induce protective immunity, even after prolonged and repeated vaccination courses. Non- responsiveness to hepati... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2020-002868-31 | Sponsor Protocol Number: 68Ga-DFO-B-I/IIa | Start Date*: 2020-10-23 |
Sponsor Name:Medizinische Universität Innsbruck | ||
Full Title: A Phase I/IIa study to evaluate safety, biodistribution, dosimetry and preliminary diagnostic performance of [68Ga]Ga-Deferoxamine for PET imaging in patients with bacterial infections | ||
Medical condition: Upper/lower respiratory tract bacterial infections or orthopaedic bacterial infections | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2012-000287-17 | Sponsor Protocol Number: RC12-01 | Start Date*: 2012-05-21 | |||||||||||
Sponsor Name:FONDAZIONE SANTA LUCIA | |||||||||||||
Full Title: PROMOTION OF FUNCTIONAL RESTORATION THROUGH PHARMACOLOGICAL MODULATION OF BRAIN PLASTICITY WITH AMINOPYRIDINE IN PATIENTS WITH MULTIPLE SCLEROSIS STUDIED BY FUNCTIONAL MRI | |||||||||||||
Medical condition: Patients with MS, without relevant medical conditions, with right upper limb impairment assessed by a hand dexterity test will be included.Patients will be in a non-active phase of the disease and ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002556-32 | Sponsor Protocol Number: ANTIC:6672 | Start Date*: 2013-09-05 | |||||||||||
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Antibiotic treatment for intermittent bladder catheterisation: A randomised controlled trial of once daily prophylaxis (The AnTIC study) | |||||||||||||
Medical condition: Recurrent urinary tract infection in people who use intermittent bladder catheterisation. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004861-25 | Sponsor Protocol Number: A4091019 | Start Date*: 2009-03-05 | |||||||||||
Sponsor Name:Pfizer Ltd., Ramsgate Road, Sandwich, Kent, CT13 9NJ, UK | |||||||||||||
Full Title: A PHASE 2, 16 WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED, PARALLEL GROUP PROOF-OF-CONCEPT STUDY EVALUATING THE EFFICACY AND SAFETY OF TANEZUMAB FOR THE TREATMENT OF PAIN ASSOCIA... | |||||||||||||
Medical condition: Chronic Abacterial Prostatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: SE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000185-11 | Sponsor Protocol Number: VX17-445-105 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Homozygous or Heterozygous for the F508del Mutation | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) NL (Completed) AT (Completed) GR (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000441-20 | Sponsor Protocol Number: TR02-108 | Start Date*: 2011-06-29 | |||||||||||
Sponsor Name:Insmed Incorporated | |||||||||||||
Full Title: Randomized, open-label, active-controlled, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas aerug... | |||||||||||||
Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) GB (Completed) BE (Completed) IE (Completed) DE (Completed) AT (Completed) GR (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001699-43 | Sponsor Protocol Number: BPR-CS-009 | Start Date*: 2018-12-13 | |||||||||||
Sponsor Name:Basilea Pharmaceutica International Ltd | |||||||||||||
Full Title: A randomized, double-blind, multi-center study to establish the efficacy and safety of ceftobiprole medocaril compared to daptomycin in the treatment of Staphylococcus aureus bacteremia, including ... | |||||||||||||
Medical condition: Complicated staphylococcus aureus bacteremia (cSAB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) BG (Completed) ES (Completed) IT (Completed) GR (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000378-30 | Sponsor Protocol Number: SMR-3372 | Start Date*: 2020-03-04 | |||||||||||
Sponsor Name:AlgiPharma AS | |||||||||||||
Full Title: A randomised, double-blind, dose finding study of inhaled alginate oligosaccharide (OligoG) vs placebo in patients with Cystic Fibrosis (CF). | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (GB - no longer in EU/EEA) IE (Completed) AT (Prematurely Ended) PL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-002202-31 | Sponsor Protocol Number: POL7080-002 | Start Date*: 2013-09-11 |
Sponsor Name:Polyphor Ltd. | ||
Full Title: A phase II, open-label, multi-center study to assess the tolerance, safety, efficacy and pharmacokinetics/pharmacodynamics (PK/PD) of POL7080 in the treatment of patients with acute exacerbation of... | ||
Medical condition: Acute exacerbation of non-cystic fibrosis bronchiectasis due to Pseudomonas aeruginosa infection. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) ES (Prematurely Ended) DE (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
